Company intelligence / Profile preview

GoodCap Pharmaceuticals

Toronto, Ontario, Canadagoodcap.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GoodCap's lead candidate GCAP001 has demonstrated significant downregulation of key pro-inflammatory cytokines in preclinical models. The company is leveraging known safety profiles of its components to expedite clinical entry. Published peer-reviewed data support the anti-inflammatory effects of their combination approach using low-dose psilocybin and eugenol. Human clinical results are pending.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (including low-dose psychedelics such as psilocybin)Combination therapies with potentiator molecules and anti-inflammatory agents
Industry: Biotech

Drug pipeline

1 asset

GCAP001

Preclinical

Partnerships

University of Toronto – academic R&D partnership supported by NSERC Alliance Grant for $237K CAD focused on preclinical evaluation of combination therapies targeting inflammation-driven depression/PTSD.

Beyond the preview

Go deeper on GoodCap Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GoodCap Pharmaceuticals.

Explore the full profile